Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
G
228760
vs
K
KOSPI 200
Over the past 12 months, Genomictree Inc has underperformed KOSPI 200, delivering a return of -51% compared to KOSPI 200's +56% growth.
Stocks Performance
228760 vs KOSPI 200
Performance Gap
228760 vs KOSPI 200
Performance By Year
228760 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Genomictree Inc
Glance View
Genomictree is a South Korean molecular diagnostics company focused on cancer detection. It develops and sells DNA methylation-based tests that look for early signs of cancer in patient samples, including blood, urine, or tissue, depending on the product. Its core business is helping hospitals and diagnostic labs identify cancer sooner and with more objective lab testing. The company makes money mainly by selling diagnostic kits and related testing products to hospitals, medical laboratories, and other healthcare customers. In some cases, it may also earn revenue from test services, licensing, or partnerships tied to its technology. Its customers are the medical professionals and institutions that need reliable lab tools for screening, diagnosis, and follow-up testing. What sets Genomictree apart is its focus on epigenetic markers, especially DNA methylation, rather than only the mutation-based tests used by many other diagnostics firms. That gives it a niche role in the cancer testing value chain: it sits between biotech research and everyday clinical use, turning lab discoveries into practical tests that doctors can order.